Fig. 2 | Scientific Reports

Fig. 2

From: Phase I study of pevonedistat combined with capecitabine and oxaliplatin in patients with platinum-refractory advanced gastric cancer

Fig. 2

Water-fall plot showing the best percentage change in tumor size from baseline in individual patients. Each bar represents a single patient, with bars extending downward indicating reduction in tumor size and bars extending upwards indicating tumor growth. Patients who received pevonedistat at a dose of 20 mg/m2 (level 1) are indicated in red and those who received 15 mg/m2 (level 0) are indicated in blue.

Back to article page